

Liling Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2489709/publications.pdf>

Version: 2024-02-01

41
papers

1,931
citations

567281

15
h-index

315739

38
g-index

47
all docs

47
docs citations

47
times ranked

3241
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. <i>Clinical Cancer Research</i> , 2010, 16, 2634-2645.	7.0	463
2	Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5701-5710.	7.0	330
3	The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. <i>EMBO Molecular Medicine</i> , 2020, 12, e12421.	6.9	293
4	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	17.0	155
5	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 7363-7369.	7.0	102
6	A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12444-12456.	3.6	85
7	Disulfiram inhibits TGF- β 2-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF- κ B/Snail pathway. <i>Oncotarget</i> , 2015, 6, 40907-40919.	1.8	75
8	lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network. <i>Frontiers in Genetics</i> , 2019, 10, 850.	2.3	42
9	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	17.0	40
10	Disulfiram/copper targets stem cell-like ALDH ⁺ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6882-6893.	2.6	39
11	Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics. <i>BioMed Research International</i> , 2018, 2018, 1-14.	1.9	31
12	Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2019, 8, 5012-5022.	2.8	24
13	Epidemiologic characteristics of malignant lymphoma in Hubei, China. <i>Medicine (United States)</i> , 2018, 97, e12120.	1.0	22
14	Efficacy and Safety of a Pegasparginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2022, 8, 1035.	7.1	21
15	RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. <i>Anti-Cancer Drugs</i> , 2017, 28, 514-521.	1.4	20
16	Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in Melanoma. <i>Frontiers in Genetics</i> , 2020, 11, 1002.	2.3	16
17	Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. <i>American Journal of Hematology</i> , 2022, 97, 623-629.	4.1	15
18	Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 5209-5220.	1.9	14

#	ARTICLE	IF	CITATIONS
19	Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 734853.	2.8	14
20	A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19 Infection After Intensive Immunochemotherapy: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 924.	2.8	13
21	Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group. <i>Frontiers in Oncology</i> , 2020, 10, 583050.	2.8	12
22	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	2.8	12
23	Expression of Nischarin negatively correlates with estrogen receptor and alters apoptosis, migration and invasion in human breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 536-542.	2.1	11
24	Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study. <i>International Journal of Cancer</i> , 2021, , .	5.1	11
25	Diagnosis and Treatment of Synchronous Lymphoma and Digestive System Carcinoma: Report of Four Cases and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 1367.	2.8	10
26	Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5061-5069.	1.9	9
27	Detection of circulating tumor cells by RT-PCR significantly associated with poor prognosis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 359-364.	2.5	8
28	miR-30a/SOX4 Double Negative Feedback Loop is modulated by Disulfiram and regulates EMT and Stem Cell-like properties in Breast Cancer. <i>Journal of Cancer</i> , 2021, 12, 5053-5065.	2.5	8
29	Primitive Neuroectodermal Tumor of the Kidney With Inferior Vena Cava Tumor Thrombus. <i>Journal of the National Medical Association</i> , 2009, 101, 1291-1294.	0.8	6
30	Complete Atelectasis of the Left Lung from Anaplastic Large-Cell Lymphoma. <i>Scientific World Journal</i> , The, 2010, 10, 1332-1333.	2.1	4
31	Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma. <i>Medicine (United States)</i> , 2020, 99, e21705.	1.0	4
32	Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis. <i>Leukemia Research</i> , 2021, 111, 106693.	0.8	4
33	Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma. <i>Medicine (United States)</i> 107(14):e27431. doi:10.1093/med/107.14.e27431	1.0	4
34	GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R) Tj ETQq0 0 0 rgBTi/Overlock 10 Tf 50 1	1.0	4
35	Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement. <i>Medicine (United States)</i> , 2019, 98, e16688.	1.0	3
36	Case Report: Long-Term Response to Radiotherapy Combined With Targeted Therapy in Histiocytic Sarcoma Harboring Mutations in MAPK and PI3K/AKT Pathways. <i>Frontiers in Oncology</i> , 2021, 11, 755893.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study. <i>Cancer Medicine</i> , 2022, 11, 4134-4145.	2.8	3
38	A novel prognostic nomogram for patients with extragastric mucosa-associated lymphoid tissue lymphoma: A multicenter study. <i>Cancer Medicine</i> , 2022, 11, 3407-3416.	2.8	1
39	Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up. <i>Frontiers in Oncology</i> , 2020, 10, 1725.	2.8	0
40	Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China. <i>Blood</i> , 2020, 136, 1-1.	1.4	0
41	Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7547-7547.	1.6	0